Luciana Borio
Luciana Borio | |
|---|---|
 | |
| Born | |
| Academic background | |
| Education | George Washington University (MD) |
| Academic work | |
| Discipline | Medicine Public health |
| Sub-discipline | Infectious diseases Biodefense Health security |
Luciana Borio is a Brazilian-American infectious disease physician and public health administrator. She is a vice president at In-Q-Tel.[1] She previously served as director for Medical and Biodefense Preparedness at the National Security Council,[2] acting chief scientist of the U.S. Food and Drug Administration (FDA),[3] assistant commissioner for counterterrorism policy of the FDA, and director of FDA's Office of Counterterrorism and Emerging Threats.[dead link][4] She is known for her work advancing clinical trials,[5][6] the development of medical countermeasures for health emergencies,[7] and the public health responses to Ebola and Zika outbreaks.[8]
On November 9, 2020, U.S. president-elect Joe Biden named Borio to be one of the 13 members of his COVID-19 Advisory Board.[9]
Early life and education
Borio obtained her MD in 1996 from George Washington University. She completed residency in 1999 in internal medicine at the Weill Cornell Medical Center and subsequently completed a combined fellowship in infectious diseases at Johns Hopkins University and critical care medicine at the National Institutes of Health. Borio continues to practice medicine at Johns Hopkins Hospital.[10]
Career
Borio is an infectious disease physician.[11] Prior to joining FDA's Center for Biologics Evaluation and Research in 2008, Borio was senior associate at the UPMC Center for Health Security and assistant professor of medicine at the University of Pittsburgh (2003–2008). Borio served at the United States Department of Health and Human Services as an advisor on biodefense programs (2001 to 2008), where she implemented and managed mathematical modeling projects to assess the health effects of bioterrorism on civilians and to inform medical countermeasures procurement activities for the Office of Preparedness and Response.[12] Before leaving her role as assistant commissioner of FDA, she approved a partnership in infectious disease research with the Bill & Melinda Gates Foundation.[13]
In 2020, Borio was appointed by the Council on Foreign Relations to serve on its Independent Task Force on Improving Pandemic Preparedness, co-chaired by Sylvia Mathews Burwell and Frances Townsend.[14]
Other activities
- Codagenix, Member of the Scientific Advisory Board[15]
- Goldman Sachs, Consultant[16]
References
- ^ Borio, Luciana; Gottlieb, Scott (January 28, 2020). "Act now to prevent an American epidemic". Wall Street Journal. Retrieved 2020-01-30.
- ^ "Key Global Health Positions and Officials in the U.S. Government". Kaiser Family Foundation. Retrieved 2018-07-28.
- ^ "Examining the U.S. Public Health Response to the Zika Virus: U.S. Food and Drug Administration Testimony before U.S. House of Representatives". U.S. Food and Drug Administration. Retrieved 2018-07-28.
- ^ [dead link]"Meet Luciana Borio, M.D., Assistant Commissioner for Counterterrorism Policy". U.S. Food and Drug Administration. Retrieved 2013-10-04.
- ^ "Luciana Borio: FDA's Role in Increasing Clinical Trial Diversity". U.S. Food and Drug Administration. Retrieved 2018-07-28.
- ^ "You may hold the cure for the next epidemic". TEDxUSU. Retrieved 2018-07-28.
- ^ "Borio interview". Johns Hopkins University Center for Health Security. Retrieved 2018-07-28.
- ^ September 17, 2014, U.S. House of Representatives Committee on Foreign Affairs, Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations hearing entitled “Global Efforts to Fight Ebola”; October 16, 2014, U.S. House of Representatives Energy and Commerce Committee, Subcommittee on Oversight and Investigations hearing entitled “Examining The U.S. Public Health Response to the Ebola Outbreak;” November 19, 2014, U.S. House of Representatives Committee on Energy and Commerce, Subcommittee on Health hearing entitled “Examining Medical Product Development in the Wake of the Ebola Epidemic;” February 26, 2015, U.S. Senate Committee on Health, Education, Labor and Pensions hearing entitled “Medical and Public Health Preparedness and Response: Are We Ready for Future Threats?” March 02, 2016, US House of Representatives Committee on Energy and Commerce, Subcommittee on Oversight and Investigations hearing entitled “Examining the U.S. Public Health Response to the Zika Virus.”
- ^ Mucha, Sarah (November 9, 2020). "Biden transition team announces coronavirus advisers, including whistleblower Rick Bright". CNN. Retrieved 9 November 2020.
- ^ "Luciana Borio, MD". WebMD. Retrieved 2013-10-04.
- ^ Gamboa, Suzanne (November 9, 2020). "Two Latino physicians and disease experts are part of Biden's Covid-19 task force". NBC News. Retrieved 2020-11-10.
- ^ "Dr. Luciana Borio: Faces Behind MCMi". U.S. Food and Drug Administration. Retrieved 2013-10-04.
- ^ "Mou 225-17-019". FDA. 3 November 2018.
- ^ Independent Task Force Report No. 78 – Improving Pandemic Preparedness: Lessons From COVID-19 Council on Foreign Relations, October 2020.
- ^ Luciana Borio, Senior Fellow for Global Health Council on Foreign Relations, October 2020.
- ^ Luciana Borio, Senior Fellow for Global Health Council on Foreign Relations, October 2020.
External links
- Appearances on C-SPAN
- Luciana Borio Outlines the Evolving Role of the FDA in Developing Medical Countermeasures upmchealthsecurity.org